- Home
- STI vs KLRS Comparison
STI vs KLRS Comparison
Compare STI & KLRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STI
- KLRS
- Stock Information
- Founded
- STI 2014
- KLRS 2019
- Country
- STI United States
- KLRS United States
- Employees
- STI N/A
- KLRS N/A
- Industry
- STI
- KLRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- STI
- KLRS Health Care
- Exchange
- STI NYSE
- KLRS Nasdaq
- Market Cap
- STI 14.0M
- KLRS 129.0M
- IPO Year
- STI N/A
- KLRS N/A
- Fundamental
- Price
- STI $0.16
- KLRS $4.06
- Analyst Decision
- STI
- KLRS Buy
- Analyst Count
- STI 0
- KLRS 1
- Target Price
- STI N/A
- KLRS N/A
- AVG Volume (30 Days)
- STI 24.8M
- KLRS 62.9K
- Earning Date
- STI 06-06-2025
- KLRS 05-19-2025
- Dividend Yield
- STI N/A
- KLRS N/A
- EPS Growth
- STI N/A
- KLRS N/A
- EPS
- STI N/A
- KLRS N/A
- Revenue
- STI N/A
- KLRS N/A
- Revenue This Year
- STI N/A
- KLRS N/A
- Revenue Next Year
- STI N/A
- KLRS N/A
- P/E Ratio
- STI N/A
- KLRS N/A
- Revenue Growth
- STI N/A
- KLRS N/A
- 52 Week Low
- STI $0.08
- KLRS $4.19
- 52 Week High
- STI $2.50
- KLRS $24.15
- Technical
- Relative Strength Index (RSI)
- STI 61.26
- KLRS N/A
- Support Level
- STI $0.09
- KLRS N/A
- Resistance Level
- STI $0.12
- KLRS N/A
- Average True Range (ATR)
- STI 0.02
- KLRS 0.00
- MACD
- STI 0.01
- KLRS 0.00
- Stochastic Oscillator
- STI 82.93
- KLRS 0.00
About STI SOLIDION TECHNOLOGY INC
Solidion Technology Inc is engaged in researching, developing and manufacturing battery materials and components, as well as the development and production of next-generation batteries for energy storage systems and electric vehicles for ground, air, and sea transportation. It is recognized as a IP leader in both the high-capacity anode and the high-energy solid-state battery.
About KLRS Kalaris Therapeutics Inc. Common Stock
Kalaris Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing therapeutics. Kalaris is developing TH103, a novel, clinical stage anti-vascular endothelial growth factor (VEGF) drug, engineered to potentially provide longer lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body native, highest affinity VEGF receptor 1.